retina

Contrast sensitivity device exposes vision limitations of reattachment patientsComputerized testing of contrast sensitivity function using the Sentio Platform (Adaptive Sensory Technology) may better quantify the visual limitations of patients than traditional letter acuity after retinal detachment repair.
Endoscope offers versatility over microscope for retinal surgeries
Isopropyl nitrate poppers pose maculopathy riskPoppers containing isopropyl nitrate may cause foveal maculopathy, researchers say.
Clinical findings supported by new OCTA technology
Clinical findings supported by new OCTA technologySince its FDA clearance, the significant potential of OCTA has been emphasized.
OCTA: Future Is bright, fast, and wide in ROPAdvances in optical coherence tomography (OCT) and OCT angiography (OCTA) may enable more objective and accurate diagnosis of ROP in the future.
Subretinal therapy offers promise of lighter treatment burden for AMDRGX-314 gene therapy offers patients the potential for a lower treatment burden with one subretinal injection of a gene therapy delivering an anti-vascular endothelial growth factor protein.
Hypersonic vitrector holds potential for multiple benefitsBausch + Lomb has introduced an ultrasonic-powered hypersonic vitrectomy system that is driven exclusively by the company’s Stellaris Elite Vision Enhancement System. It has a novel mechanism of action and is expected to offer advantages compared with guillotine vitrectors, according to the company.
Novel DME treatment derives from multimodal activityALG-1001 is an integrin receptor inhibitor that acts to stabilize the retina’s response to diabetes-related hypoxic and oxidative stress, mitigating production of a host of molecules involved in the development of diabetic macular edema.
Investigational trials target VEGF/angiopoietin2 inhibition
Intravitreal brimonidine holds promise for slowing GA growthBrimonidine Drug Delivery System (Brimo DDS) in an intravitreally administered, sustained-release implant (Allergan) shows promise as a treatment for geographic atrophy (GA), secondary to age-related macular degeneration in a phase IIa clinical trial.
var script= ' ';